Stay Informed

Sign up for news & alerts

Already signed up?
Login here
What Can I Do?


Get Help
Need alcohol or drug help for yourself or someone else? GET HELP
Resources
Resources
Find useful publications, online documents & more.


DrugScreening.org


 

California Senate Approves OD Prevention Bill
June 8, 2007

Email
Email
Print
Print
SubscribeSubscribe
News Summary

The California Senate has unanimously approved a bill that would provide legal cover to doctors who prescribe the drug naloxone (Narcan) to drug-overdose victims.

The Drug Policy Alliance reported June 6 that the state Senate approved the bill, SB-767, by a 39-0 vote. The bill was sponsored by state Sen. Mark Ridley-Thomas (D-Los Angeles).

"Clinicians are concerned about civil or criminal liability if a patient uses his or her naloxone on someone else," noted the Harm Reduction Coalition, which backed the measure. "Because of this concern there aren't enough clinicians willing to prescribe naloxone for all the agencies that want to incorporate overdose programs into their services, but there will be once SB 767 passes."

The group added that the legislation also would make it easier for people who witness an opiate overdose to access naloxone and administer it to victims. 

COMMENTS ON THIS ARTICLE:

Your Turn! Post a public comment (read guidelines):

Name:

Comment:
(limit 200
words)

Enter this word
(help):
Change

GUIDELINES: 
To keep this feature useful for everyone, please:

  1. Keep it clean, courteous, focused, and on-topic. Comments are meant for thoughtful discussion of the article published above.

  2. Do not post personal requests for help or general promotions for your organization (Get help).

  3. Proof your comments carefully, use good spelling and punctuation, and don't use ALL CAPS. Comments are published immediately and cannot be edited.

Deceptive, slanderous and commercially-motivated posts are prohibited. We reserve the right to remove comments not conforming to these guidelines. (Report a comment).

Have questions or feedback? Contact us.